Trial Number

790-17

Condition

Prostate Cancer

Participant Age Range

21 Years and older

Participant Gender

Male

Enrolling Participants

Yes

Overview

Prospective Evaluation of TrueBeam / Edge Stereotactic Body Radiotherapy for Localized Prostate Cancer: Risk Stratified Monotherapy versus Radiosurgery Boost

The primary safety purpose of this study is to estimate the rates of immediate and long-term high grade (grade 3-5) gastrointestinal and genitourinary side effects during the five years after TrueBeam stereotactic body radiotherapy in low-risk and intermediate-risk prostate cancer patients. The primary efficacy purpose is to compare 5 year biochemical disease free survival rates with TrueBeam to 5 year biochemical diseases free survival rates with dose-escalated external beam radiation therapy.

Provider

Name
Address
Enter Trial number from the area just below the marquee.
How would you prefer to be contacted?
How did you hear about us?
Are you a current MemorialCare patient?
This registration is for:
CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.